Sandoz Cuts Full-Year Sales Growth Outlook; Shares Fall 8%
Sandoz lowered its full-year sales growth guidance after short-term biosimilar-supply constraints weighed on third-quarter results. Shares fell as much as 8% on Wednesday.
By Marleen KaesebierSwiss generic drugmaker Sandoz BX:D8Y lowered its full-year sales growth guidance after short-term biosimilar-supply constraints weighed on third-quarter results, sending shares down as much as 8% on Wednesday.The company now expects net sales to grow by 5-6% at constant exchang…